Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Macrogenics

Key Facts as at 30.09.2025

Company locationUSA
Size in % of securities0.60%
Size of stake in company15.70%
Market capitalizationUSD 105 mn

Sector

Oncology

Main candidate

Vobramitamab Duocarmazine 

Main indications

Metastatic castration resistant prostate cancer (mCRPC)

About the company

Macrogenics is a biotechnology company focused on the discovery and development of innovative antibody-based therapeutics designed to modulate the immune response for the treatment of cancer. The company was founded in 2000 and is headquartered in Maryland in the US. Macrogenics´ expertise is in the field of protein engineering and the company has developed DART bispecific and Fc Optimization technology platforms. These technology platforms are focused on the creation of antibodies, antibody derivatives, and antibody-like molecules. Macrogenics has multiple product candidates in clinical development with Vobramitamab Duocarmazine, an Antibody Drug Conjugate (ADC) targeting B7H3 for patients with mCRPC being the most advanced one. The currently ongoing Phase II is expected to read-out in 2024.

Disclaimer

All comments as at December 31, 2024 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.